Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma

Aparicio, Jorge; Muro, Xavier García del; Maroto, Pablo; Paz‐Ares, Luis; Alba, Emilio; Saenz, A.; Terrasa, Josefa; Barnadas, A.; Almenar, D.; Arranz, José Ángel; Sánchez, Miguel Ángel Goenaga; Fernández, Antonio; Sastre, Javier; Carles, Joan; Dorca, Joan; Gumà, Josep; Yuste, Ana; Germà, J.R.

doi:10.1093/annonc/mdg241

Cited by 116 publications

(54 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] Three were randomized controlled trials, 9 were phase 2 trials, and 5 were from prospective institutional databases. For purposes of summary data generation, these studies included a total of 5561 patients ( Table 2).…”

Section: Study Characteristicsmentioning

confidence: 99%

Evidence‐based guidelines for following stage 1 seminoma

Martin

Panzarella

Zwahlen

et al. 2007

Cancer

View full text Add to dashboard Cite

A chemically crosslinked biodegradable hydrogel was prepared via a macromer technique, and physicochemical characterizations associated with its potential application as an injectable biomaterial were carried out. The macromers were composed of poly(ethylene glycol) extended with oligomers of biodegradable polyesters such as oligolactide and end‐capped with acryloyl groups. Hydrogels were obtained through the polymerization of the macromer aqueous solutions in phosphate‐buffered saline initiated by a redox initiator system at body temperature. The initiator system was composed of ammonium persulfate as an initiator and N,N,N′,N′‐tetramethylethylene diamine as an accelerator. The modulus of this chemical gel was much higher than that of a Pluronic physical gel. In vitro biodegradation was also confirmed. The degradation rates were highly tunable by the adjustment of several factors, such as the kind of ester group, the block length of the oligoester, and even the concentration of the accelerator used in the crosslinking reaction. The gelation time could be adjusted to meet the requirements of an injectable biomaterial. The effect of the polymerization heat seemed not to be significant. This kind of biodegradable hydrogel might be in situ formed after being injected into the body and shows potential applications as a unique tissue engineering material free of porogening techniques in scaffold fabrication and less invasive in implantation. © 2005 Wiley Periodicals, Inc. J Appl Polym Sci, 2006

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Evidence‐based guidelines for following stage 1 seminoma

Martin

Panzarella

Zwahlen

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…Patients with stage I seminoma who opt for surveillance have a greater than 80% chance of remaining relapse free at 5 years [2], and 99% of those who relapse are successfully treated with 3 cycles of BEP (bleomycin, etoposide and cisplatin). Any adjuvant treatment may be considered over-treatment for 80% of the patients.…”

Section: Discussionmentioning

confidence: 99%

Late Relapse of Stage I Seminoma following Single-Agent Carboplatin

Raj

Williams²,

Dixon³

et al. 2007

Oncology

View full text Add to dashboard Cite

We present a case report of a patient who received adjuvant carboplatin for stage 1 seminoma and relapsed with abdominal lymph node metastasis at 48 months. In recent years, many oncologists have offered a single cycle of adjuvant carboplatin AUC7 as adjuvant treatment for stage 1 seminoma. The available data show a non-inferior relapse-free survival at 3 years compared with para-aortic radiotherapy. The rate of relapse beyond this point has not been reported. Patients with stage 1 seminoma represent a group of patients with excellent outcomes, and treatment options must also consider the late effects of treatment, of which there are increasing data of mortality for those treated with radiotherapy. Patients who opt for surveillance have a greater than 80% chance of remaining relapse free at 5 years, but those on surveillance require more CT examinations for follow-up. For those treated with single-agent carboplatin, our case report highlights that late relapse can occur, and we suggest that CT surveillance beyond 2 years is required given the lack of mature data on late relapse.

show abstract

“…pacientų gali turėti subklinkines metastazes, ypač retroperitoniame tarpe [20]. Nustačius neseminominį germinogeninį naviką, subklinkinės metastazės yra dažnesnės (iki 30 proc.)…”

Section: Diskusijaunclassified

Sėklidės vėžio kombinuoto gydymo analizė

Žalimas

Kindurys

Platkevičius

et al. 2015

Medicinos Teorija Ir Praktika

View full text Add to dashboard Cite

Santrauka dešinioji -20 (45,5 proc.). Po operacijos 14 (32 proc.) pacientų histologiškai nustatyta sėklidės seminominis, 30 (68 proc.) -neseminominis germinacinių ląstelių navikas. Pagal Tarptautinės urologų asociacijos gairių siūlomą vertinimą ("International Germ Cell Cancer Collaborative Group"): geros prognozės -26 ligoniai (59 proc.), vidutinės -13 (30 proc.), blogos -5 (11 proc.). Didelių dozių chemoterapija su autologine kamieninių kraujo ląstelių transplantacija taikyta 9 (20,5 proc.) pacientams, kurie buvo blogoje prognostinėje grupėje, ir pacientams, kuriem po pradinės chemoterapijos pastebėtas ligos progresavimas. Po chemoterapijos dėl nustatytų likutinių masių 2 (4,5 proc.) pacientams atlikta plaučio rezekcija, 2 (4,5 proc.) pašalinta smegenų metastazė, 23 (52 proc.) pašalinti pakitę regioniniai retroperitoniniai limfmazgiai, 1 (2,3 proc.) pašalinti pakitę neregioniniai viršraktikauliniai limfmazgiai, o 1 (2,3 proc.) taikytas spindulinis gydymas. Vidutinis stebėjimo laikotarpis 39,4 (± 27,8) mėnesio, per kurį 40 (91 proc.) pacientų buvo pasiekta remisija, 1 (2 proc.) ligoniui progresavimo požymių įvertinti negalime, kadangi nesikreipė, ir 3 (7 proc.) pastebėtas ligos progresavimas, iš jų 2 ligoniai mirė dėl vėžinės intoksikacijos, 1 pacientui šiuo metu taikoma chemoterapija. Bendras tiriamųjų 5 metų išgyvenamumas -96 proc. Išvados. Sėklidės vėžys yra dažniausias solidinis navikas tarp jaunų vyrų. Dėl neskausmingų ankstyvų simptomų ir vengimo kreiptis į gydytoją vėžys nustatomas vėlesnių stadijų su blogesne prognoze. abStract Key words: testicular cancer, germ cell tumor, cancer markers, prognostic groups. Objective. Evaluate treatment results of testicular cancer at Vilnius university hospital Santariskiu klinikos Urology center. Patients and methods. From 2004 till 2014 at Vilnius university hospital Santariskiu klinikos Urology center 53 patients were operated due to testicular cancer. 44 patients were selected to participate in this retrospective study. General characteristics (age, diagnosis, labaratory findings, applied treatment) were obtained from patient's case-record. Results. The median age was 30.48 (± 8.59) years. Most patients complained becouse of enlarged testicle -26 (59.1 %). All patients underwent high orchofuniculectomy: 24 (59.1) -left side, 20 (45.5 %) -right side. Testicular seminoma and nonseminoma cancer on postoperative histological examination accounted for 14 (32 %) and 30 (68 %), respectively. According to International Germ Cell Cancer Collaborative Group suggested prognostic evaluation we distributed our patients into prognostic groups: 26 (59 %) -good, 13 (30 %) -intermediate and 5 (11 %) patients with poor prognosis. Due to disease progression after primary chemotherapy or poor prognosis 9 (20.5 %) patients underwent high-dose chemotherapy with autologous blood stem cell transplantation. Due to remaining post-chemotherapic abnormal masses 23 (52 %) patients had regional retroperitoneal lymph nodes dissected, 1 (2.3 %) abnormal non-regional supraclavicular lymph node wa...

show abstract

Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma

Cited by 116 publications

References 19 publications

Evidence‐based guidelines for following stage 1 seminoma

Evidence‐based guidelines for following stage 1 seminoma

Late Relapse of Stage I Seminoma following Single-Agent Carboplatin

Sėklidės vėžio kombinuoto gydymo analizė

Contact Info

Product

Resources

About